Company Overview

Update
Founded:
2006
Founders:
Roger Hawley, Jonathan M. Rigby
Headquarters:
San Diego, CA
IPO:
Went Public on Dec 3, 2010
Stock:
NASDAQ:ZGNX
Categories:
Biotechnology

Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.

Description

Update

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.

We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Current Team (6)

Update

Board Members and Advisors (4)

Update

Funding Rounds (6) - $167.10M

Update

Investors (8)

Update

Offices/Locations (1)

Update
  • HQ

    12671 High Bluff Dr

    San Diego, CA 92130

    USA

Images (1)

Update
  • 6f1f4fd774a3cde7f41f699da59548e3